Altimmune Return On Equity vs. Return On Asset

ALT Stock  USD 8.25  0.07  0.86%   
Based on the measurements of profitability obtained from Altimmune's financial statements, Altimmune may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Altimmune's ability to earn profits and add value for shareholders.
 
Return On Equity  
First Reported
2010-12-31
Previous Quarter
(0.46)
Current Value
(0.48)
Quarterly Volatility
2.73340127
 
Credit Downgrade
 
Yuan Drop
 
Covid
At this time, Altimmune's Price To Sales Ratio is comparatively stable compared to the past year. EV To Sales is likely to gain to 1,145 in 2024, whereas Days Of Sales Outstanding is likely to drop 3,652 in 2024. At this time, Altimmune's Total Other Income Expense Net is comparatively stable compared to the past year. Interest Income is likely to gain to about 7.7 M in 2024, whereas Income Before Tax is likely to drop (92.9 M) in 2024.
For Altimmune profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Altimmune to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Altimmune utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Altimmune's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Altimmune over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
For more information on how to buy Altimmune Stock please use our How to Invest in Altimmune guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Altimmune. If investors know Altimmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Altimmune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.57)
Revenue Per Share
0.001
Quarterly Revenue Growth
(0.99)
Return On Assets
(0.40)
Return On Equity
(0.73)
The market value of Altimmune is measured differently than its book value, which is the value of Altimmune that is recorded on the company's balance sheet. Investors also form their own opinion of Altimmune's value that differs from its market value or its book value, called intrinsic value, which is Altimmune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Altimmune's market value can be influenced by many factors that don't directly affect Altimmune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Altimmune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Altimmune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Altimmune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Altimmune Return On Asset vs. Return On Equity Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Altimmune's current stock value. Our valuation model uses many indicators to compare Altimmune value to that of its competitors to determine the firm's financial worth.
Altimmune is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At this time, Altimmune's Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Altimmune by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Altimmune Return On Asset vs. Return On Equity

Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Altimmune

Return On Equity

 = 

Net Income

Total Equity

 = 
-0.73
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Altimmune

Return On Asset

 = 

Net Income

Total Assets

 = 
-0.4
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.

Altimmune Return On Asset Comparison

Altimmune is currently under evaluation in return on asset category among its peers.

Altimmune Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Altimmune, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Altimmune will eventually generate negative long term returns. The profitability progress is the general direction of Altimmune's change in net profit over the period of time. It can combine multiple indicators of Altimmune, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-5 M-4.8 M
Operating Income-95.9 M-91.1 M
Income Before Tax-88.4 M-92.9 M
Net Loss-88.4 M-84 M
Income Tax Expense309.1 K293.6 K
Total Other Income Expense Net7.5 M9.7 M
Net Loss-88.4 M-84 M
Non Operating Income Net Other-154 K-146.3 K
Net Loss-76.2 M-72.4 M
Interest Income7.4 M7.7 M
Net Interest Income7.3 M7.7 M
Change To Netincome9.5 M10.3 M
Net Loss(1.66)(1.74)
Income Quality 0.86  0.95 
Net Income Per E B T 0.90  0.58 

Altimmune Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Altimmune. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Altimmune position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Altimmune's important profitability drivers and their relationship over time.

Use Altimmune in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Altimmune position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Altimmune will appreciate offsetting losses from the drop in the long position's value.

Altimmune Pair Trading

Altimmune Pair Trading Analysis

The ability to find closely correlated positions to Altimmune could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Altimmune when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Altimmune - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Altimmune to buy it.
The correlation of Altimmune is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Altimmune moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Altimmune moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Altimmune can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Altimmune position

In addition to having Altimmune in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Casinos Thematic Idea Now

Casinos
Casinos Theme
Companies that are related to providing casino-type services across multiple geographical areas. The Casinos theme has 51 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Casinos Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Altimmune Stock Analysis

When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.